`
`Please read carefully and keep th is
`insert for future reference
`
`NAPHCON
`EYE A. DROPS
`
`Relieves Redness & Itching
`EYE ALLERGY RELIEF
`CLINICALLY PROVEN
`
`Accidental swallowing by infants and children may
`lead to coma and marked reduction in body
`temperature. Before using in children under 6 years of
`age, consult your physician. Keep this and all drugs
`out of the reach of children.
`If swallowed, get medical help or contact a Poison
`Control Center right away.
`Remove contact lenses before using.
`Store at 20° - 25°C (68° - 7TF).
`Protect from light.
`Use before the expiration date marked on the carton or
`bottle.
`
`Alcori
`
`For the tempo rary relief of the minor eye symptoms of
`itching and redness caused by ragweed, pollen, grass,
`animal dander
`and hair.
`DESCRIPTION: Active: Naphazoline Hydrochloride
`0.025%, Phenlramine Maleate 0.3%. Preservative:
`Benzalkonium Chloride 0.01 %. Inactive: Boric Acid,
`Edetate Disodium 0.01% , Purified Water, Sodium
`Borate, Sodium Chloride, Sodium Hydroxide and/or
`Hydrochloric Acid (to adjust pH). The sterile
`ophthalmic solution has a pH of about 6 and a ton lclty
`of about 270 mOsm/Kg.
`DIRECTIONS:
`Put 1 or 2 drops in the affected eye(s) up to 4 times
`every day.
`WARNINGS:
`To avoid contamination, do not touch tip of container
`to any surface. Replace cap after using.
`If solution changes color or becomes cloudy, do not use.
`Stop use and ask a doctor if you fee l eye pain, changes
`In vision occur, redness or irritation of the eye(s) gets
`worse or lasts more than 72 hours.
`When using this product, pupils may become enlarged
`temporarily. Overuse may cause more redness of the
`eye(s).
`If you are sensitive to any ingredient in this product,
`do not use. Do not use this product if you have heart
`disease, high blood pressure, narrow angle glaucoma,
`or trouble urinating unless directed by a physician.
`
`Alcori
`
`ALCON LABORATORIES, INC.
`FORT WORTH, TX 76134 USA
`© 2002, 2004-2005, 2007, 2012-2013 Novartis
`
`9009268 -0 313
`
`Slayback Exhibit 1058, Page 1 of 1
`Slayback v. Eye Therapies - IPR2022-00142
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
